By Professor Paul De Souza

Conference Abstracts

Fatima S; Gamage K; Sajinovic M; Herman D; Scott K; Desouza P, 2024, 'TARGETTING GLIOBLASTOMA MULTIFORME USING A MULTIACTION ANTICANCER ANTI-INFLAMMATORY THERAPEUTIC STRATEGY', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, TX, Houston, Vol. 26, presented at 29th Annual Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), TX, Houston, 21 November 2024 - 24 November 2024, http://dx.doi.org/10.1093/neuonc/noae165.0503

Lee DH; Roohullah A; Cho BC; Lee S-H; Lemech C; De Souza P; Millward M; Choi J; Park KE; Kim E; Kim NY; Shin YK; Han J-Y, 2022, 'A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1096 - S1096, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1320

Lee DH; Roohullah A; Cho BC; Lemech CR; de Souza PL; Millward M; Choi JY; Park KE; Kim NY; Kim E; Lee S; Kim Y; Shin YOUNGKEE; Han J-Y, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3105 - 3105, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3105

Gu S; de Souza PL; Shi Y; Han W; Luo S; Chen J; Day D; Frentzas S; Park JJ; Shao G; Wu S; Fang M; Haydon AM; Sun S; Lei K; Ding L; Zuo R; Gan X; Zhao Y; Chen X, 2022, 'A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 2641 - 2641, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.2641

Vasselli JR; Frentzas S; Weickhardt AJ; de Souza PL; Tang J; Wyant T; Amit I; Ofran Y; Knickerbocker A, 2022, 'Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS2671 - TPS2671, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps2671

Powderly JD; de Souza PL; Gutierrez R; Horvath L; Seitz L; Ashok D; Park A; Walters MJ; Karakunnel JJ; Berry W; Rieger A; Garofalo A; Lai DW; Chaudhry A, 2019, 'AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2604

Rachumalla PR; Carson E; Cooper A; Wilkinson K; Asghari R; Adams D; Ng W; Chua W; Roohullah A; De Souza P, 2018, 'Retrospective analysis of clinical characteristics and outcomes for patients enrolled in oncology phase 0 and phase 1 clinical trials at Liverpool Cancer Therapy Centre', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 168 - 169, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200283&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carson E; Cooper A; De Souza P; Chua W, 2017, 'Retrospective Analysis of Clinical Characteristics and Outcomes for Patients Enrolled on Oncology Phase I Clinical Trials at Liverpool Hospital Cancer Therapy Centre', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 117 - 117, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Brungs D; Healey E; Rose J; Tubaro T; Ng W; Chua W; Carolan M; de Souza P; Aghmesheh M; Ranson M, 2016, 'Adjuvant chemotherapy for stage III colorectal cancer in the elderly', in Annals of Oncology, Vol. 27, pp. vi182, http://dx.doi.org/10.1093/annonc/mdw370.101

Revoltar M; Shin J-S; Lim S; Tut T-G; Dissanayake I; Descallar J; Ho V; Chua W; Ng W; Lee M; Henderson C; De Souza P; Morgan M; Lee CS, 2016, 'Early marker of DNA damage response, atm, as a predictor of clinical outcome following radiotherapy in rectal cancer patients.', in Pathology, England, Vol. 48 Suppl 1, pp. S153, England, http://dx.doi.org/10.1016/j.pathol.2015.12.417

Lim SH; Spring K; Chua W; Ng W; Descallar J; Ma Y; Becker TM; De Souza P, 2015, 'Circulating Tumor Cells in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, TX, San Antonio, Vol. 93, pp. E522 - E523, presented at 57th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), TX, San Antonio, 18 October 2015 - 21 October 2015, http://dx.doi.org/10.1016/j.ijrobp.2015.07.1883

Lim SH; Ng W; Chua W; Descallar J; Spring K; De Souza P, 2015, 'Psychological parameters and circulating tumor cells in locally advanced rectal cancer', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, Vol. 11, pp. 57 - 57, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

De Souza P; Smith MR; Fizazi K; Saad F; Mulders PFA; Sternberg CN; Miller K; Logothetis CJ; Shore N; Small EJ; Carles J; Flaig TW; Taplin M-E; Higano CS; De Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE; Ryan CJ, 2015, 'Final analysis of the randomised, phase 3, COU-AA-302 study of abiraterone acetate (AA) in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC)', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Adelaide, Vol. 115, pp. 21 - 22, presented at 68th Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Adelaide, 11 April 2015 - 14 April 2015

Basch EM; Sholz MC; De Bono JS; Vogelzang NJ; De Souza PL; Marx GM; Vaishampayan UN; George S; Schwarz JK; Antonarakis ES; O'Sullivan JM; Kelabasty AR; Chi KN; Dreicer R; Hutson TE; Mangeshkar M; Holland JS; Weitzman A; Scher HI, 2015, 'Final analysis COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel(D) and abiraterone (A) and/or enzalutamide (E)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, Vol. 33, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.141

Lim S; Chua W; Ng W; Descallar J; Bokey L; Spring K; De Souza P, 2015, 'Presence of circulating tumour cells and correlation with inflammatory markers in non-metastatic rectal cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, Vol. 51, pp. S391 - S391, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)31092-9

Lim S; Ng W; Chua W; Descallar J; Spring K; De Souza P, 2015, 'Quality of life and circulating tumour cells in patients treated with neoadjuvant chemoradiation for rectal cancer - is there a link?', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, Vol. 51, pp. S224 - S224, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)30648-7

Back to profile page